title: Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane.
abstract: Aseptic loosening remains the primary cause of failure in total joint arthroplasty. Implant-derived particles are thought to be a main cause of osteolysis that leads to the failure. Substance P (SP) immunoreactive nerve fibers have been detected in the periprosthetic membrane of aseptic loose hip prostheses. We isolated fibroblasts from periprosthetic membrane. Fibroblasts were examined by real-time RT-PCR and enzyme-linked immunosorbent assay for expression of the receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG), cyclooxygenase (COX)-1, and COX-2. Experiments were performed in the presence and absence of titanium particles, SP and NS-398 (a selective COX-2 inhibitor). Titanium particles or SP stimulated RANKL and COX-2 expression in fibroblasts, whereas NS-398 inhibited RANKL production, suggesting a COX-2-mediated event. Moreover, SP enhanced COX-2 and RANKL expression by titanium particles-stimulated fibroblasts. Thus, SP and titanium particles acted synergistically to increase RANKL expression.
authors.affiliation: Department of Orthopaedic Surgery, Sixth People's Hospital, College of Medcine, Shanghai Jiao Tong University , Shanghai , China.
authors.forename: Yebin
authors.initials: Y
authors.lastname: Qian
authors.forename: Xian-long
authors.initials: XL
authors.lastname: Zhang
authors.forename: Bing-Fang
authors.initials: BF
authors.lastname: Zeng
authors.forename: Yao
authors.initials: Y
authors.lastname: Jiang
authors.forename: Hao
authors.initials: H
authors.lastname: Shen
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
mesh_terms: D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D009578:Nitrobenzenes / Q000494:pharmacology; D010641:Phenotype; D053245:RANK Ligand / Q000235:genetics* / Q000378:metabolism; D013373:Substance P / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D014025:Titanium / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D009578:Nitrobenzenes; D053245:RANK Ligand; D013449:Sulfonamides; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D013373:Substance P; D014025:Titanium; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human